High serum levels of TNF-α and IL-6 predict the clinical outcome of treatment with human recombinant erythropoietin in anaemic cancer patients

Annals of Oncology

Volumn 21, Issue 7, 2009, Pages 1523-1528

  Pavese, I ^a   Satta, F ^a   Todi, F ^a   Di Palma, M ^a   Piergrossi, P ^a   Migliore, A ^a   Piselli, P ^a   Borghesi, R ^a   Mancino, G ^a   Brunetti, E ^a   Alimonti, A ^a  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Cytokines; Erythropoiesis stimulating agents; RHUEPO; Treatment outcome

Indexed keywords

HEMOGLOBIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTATE DEHYDROGENASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; CANCER FATIGUE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE COUNT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; OUTCOME ASSESSMENT; PREDICTION; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; SELF EVALUATION; TUMOR LOCALIZATION;

EID: 77954264931     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp568     Document Type: Article

References (27)

1. Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003; 14: 511-519.
2. Cella D, Zagari MJ, Vandoros C et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003; 21: 366-373.
3. Quirt I, Robeson C, Lau CY et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001; 19: 4126-4134.
4. Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet 2003; 362: 640-650.
5. Patrick DL, Gagnon DD, Zagari MJ et al. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003; 39: 335-345.
6. Fallowfield L, Gagnon D, Zagari M et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 2002; 87: 1341-1353.
7. Rizzo JD, Somerfield MR, Hagerty KL et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008; 26: 132-149.
8. Lacombe C. Resistance to erythropoietin. N Engl J Med 1996; 334: 660-662.
9. Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80: 1639-1647.
10. Lee SJ, Kwon JH, Jung CW. Erythropoietin response is inadequate in cancer patients receiving chemotherapy. Int J Hematol 2001; 74: 416-420.
11. Means RT Jr, Krantz SB. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest 1993; 91: 416-419.
12. Means RT Jr, Krantz SB. Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood 1991; 78: 2564-2567.
13. Means RT Jr, Dessypris EN, Krantz SB. Inhibition of human colony-formingunit erythroid by tumor necrosis factor requires accessory cells. J Clin Invest 1990; 86: 538-541.
14. Johnson CS, Pourbohloul SC, Furmanski P. Negative regulators of in vivo erythropoiesis: interaction of IL-1 alpha and TNF-alpha and the lack of a strict requirement for T or NK cells for their activity. Exp Hematol 1991; 19: 101-105.
15. Means RT Jr, Krantz SB, Luna J et al. Inhibition of murine erythroid colony formation in vitro by interferon gamma and correction by interferon receptor immunoadhesin. Blood 1994; 83: 911-915.
16. Mendoza TR, Wang XS, Cleeland CS et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999; 85: 1186-1196.
17. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003; 98: 1072-1079.
18. Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914-924.
19. Broxmeyer HE, Williams DE, Lu L et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. J Immunol 1986; 136: 4487-4495.
20. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79: 1987- 1994.
21. Nemeth E, Rivera S, Gabayan V et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-1276.
22. Pietrangelo A, Trautwein C. Mechanisms of disease: the role of hepcidin in iron homeostasis-implications for hemochromatosis and other disorders. Nat Clin Pract Gastroenterol Hepatol 2004; 1: 39-45.
23. Ludwig H, Fritz E, Leitgeb C et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84: 1056-1063.
24. Stasi R, Brunetti M, Bussa S et al. Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clin Lab Haematol 1997; 19: 197-201.
25. Musto P, Matera R, Minervini MM et al. Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin. Haematologica 1994; 79: 265- 268.
26. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 2001; 92: 1684-1688.
27. Cleeland CS, Bennett GJ, Dantzer R et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003; 97: 2919-2925.